Denise Myshko

Certain patients with RAS wild-type colorectal cancer should be treated with bevacizumab in place of cetuximab in combination with FOLFOXIRI.

Results of a phase 1/2 trial presented at the 2021 ASCO Annual Meeting show the feasibility of an approach targeting CLL-1 cells in pediatric patients with relapsed or refractory acute myeloid leukemia.

Patients with non‒small cell lung cancer with undetectable circulating tumor MET Exon 14 following treatment with savolitinib are more likely to have positive progression-free and overall survival outcomes.

Adjuvant therapy with nivolumab was superior to placebo for improving disease-free survival in patients with muscle-invasive urothelial carcinoma.

The MET inhibitor tepotinib demonstrated durable clinical activity in non‒small cell lung cancer tumors harboring MET exon 14 skipping mutations.

Data from the APHINITY trial suggested that patients with early breast cancer with a HER2 single-activated pathway determined by molecular subtyping using BluePrint assay demonstrated a trend for greater benefit with adjuvant pertuzumab (Perjeta) therapy.

Azacitidine, was shown to significantly prolong overall survival and relapse-free survival in patients with acute myeloid leukemia in first remission regardless of the number of rounds of prior consolidation therapy.